ArticleNMR in biomedicine2026
Pulmonary Vein Flow Indices by MRI for Diastolic Function Evaluation.
Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Transthoracic echocardiography (TTE) is the first-line and most useful imaging modality for evaluating diastolic dysfunction, but its ability to measure pulmonary vein (PV) flow is limited. We sought to establish MRI-based PV flow for diastolic dysfunction by comparing it to TTE and evaluating its performance in patients. First, near same-day (2 ± 3 days) dedicated TTE and MRI were performed in a young cohort (N = 12, 36 ± 20 years old) for comparison of PV flow measurements at 3 T. Secondly, an older healthy cohort (N = 11) was also evaluated for PV flow. Finally, 21 patients with a recent TTE (within 4 months) were prospectively enrolled from 2019 to 2022 and imaged at 1.5 T to measure PV flow. In these patients, a dedicated phase-contrast scan was performed to assess PV flow as an addition to their clinical scan. With near same-day dedicated TTE and MRI to measure PV velocity and flow, S/D (measured by total flow) agreed moderately between TTE and MRI (r = 0.72, p = 0.03, N = 12), and the average S/D was 1.2 ± 0.4. The Bland-Altman limits of agreement revealed bias ±2 SD = 0.13 ± 0.64 mL/s. MRI-based S/D using peak velocity was highly correlated to S/D by total flow (R = 0.97, p < 0.001) in this cohort. Six of 21 patients had LV diastolic dysfunction (four indeterminate, two with Grade II dysfunction). S/D (by flow) was not different in patients with DD vs. without (1.5 ± 0.6 vs. 1.4 ± 0.5) or in healthy age-matched controls (1.5 ± 0.6). The D wave DT (by flow) was prolonged in patients with diastolic dysfunction vs. patients without (253 ± 42 ms vs. 207 ± 41 ms, p < 0.05) and was 225 ± 61 in healthy age-matched controls. In ROC analysis, D wave DT > 241 ms provided an AUC of 0.78 to predict patients with LV diastolic dysfunction. PV flow by MRI has potential to be a useful method for diastolic function evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.